Revenue segments as reported by the company.

Premiums earned, net

Other income

Investment income, net

Direct Contracting revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Net medical claims incurred

Salaries and benefits

General and administrative expenses

Premium deficiency reserve (benefit) expense

Depreciation and amortization

Other expense

Restructuring costs

Impairment of goodwill and other intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Clover Health Investments

Clover Health Investments Corp. provides healthcare insurance services. It uses its proprietary technology platform to collect, structure, and analyze health and behavioral data to improve medical outcomes and lower costs for patients. The company was founded on July 17, 2014 and is headquartered in Franklin, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clover Health reports profitable Q1, poised for sustained growth

Clover Health Investments had a strong Q1 performance, expecting full-year profitability and revenue growth. With a focus on operational enhancements, revenue growth, and cost reductions, the company aims to maintain momentum in 2024 amidst industry challenges. Clover's strategic initiatives like share repurchase program and product enhancements position it well for sustained growth and care management excellence.

Clover Health achieves profitability milestone and eyes market expansion

Clover Health's Q2 2024 earnings call reflects a positive trajectory with increased profitability, strong revenue growth, and improved guidance for the full year.
The company's strategic focus on operational efficiency, technology innovation, and market validation positions it well for sustainable growth and market expansion.
While facing challenges in maintaining profitability and implementing technology enhancements, Clover Health has opportunities to capitalize on market interest and drive further growth in the Medicare Advantage sector.

Clover Health reports strong Q3 performance and eyes growth opportunities

Clover Health Investments (CLOV) showcased strong financial performance and strategic investments in growth areas during the Q3 2024 earnings call. The company's focus on membership growth, quality initiatives, and technology enhancements, along with exploring health partnerships, highlights a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clover Health Investments Corp. is a physician enablement technology company that provides Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. Clover Health Investments was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Franklin, TN.

Clover Health (NASDAQ: CLOV ) co-founder and Executive Chairman Vivek Garipalli bought 531,700 shares of his troubled health insurance company this month. The executive now owns over 1.4 million shares.

CLOV Stock Alert: What to Know About Clover Health's Big Insider Buy

Clover Health Investments (CLOV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Clover Health Investments, Corp. (CLOV) Hit a 52 Week High, Can the Run Continue?

Clover Health Investments (CLOV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Clover Health Investments (CLOV) Is Attractively Priced Despite Fast-paced Momentum

GE HealthCare Technologies Inc

Twist Bioscience Corp

Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Ryan Schmidt - IR Andrew Toy - CEO Peter Kuipers - CFO Conference Call Participants Richard Close - Canaccord Genuity Inc. Jason Cassorla - Citigroup Whit Mayo - Leerink Partners Operator Ladies and gentlemen good afternoon, and welcome to the Clover Health Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode.

Clover Health Investments, Corp. (CLOV) Q2 2024 Earnings Call Transcript

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.06 per share a year ago.

Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates

Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7.2 million versus Second Quarter 2023 GAAP loss of $28.9 million Adjusted EBITDA profitability for the Second Quarter of 2024 of $36.2 million versus Second Quarter 2023 Adjusted EBITDA of $9.9 million Increases Full-Year 2024 guidance to Insurance Revenue of $1.35 billion - $1.375 billion and Adjusted EBITDA profitability of $50 million - $65 million FRANKLIN, Tenn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today reported financial results for the second quarter 2024.

Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance

FRANKLIN, Tenn., July 24, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its participation in the following investor conferences:

Clover Health to Participate in Upcoming 2024 KeyBanc Technology Leadership Forum and Canaccord Genuity 44th Annual Growth Conference

FRANKLIN, Tenn., July 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2024 financial results after market close on Monday, August 5, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on August 5, 2024, to discuss Clover Health's business and financial results.

Clover Health to Report Second Quarter 2024 Financial Results on August 5

FRANKLIN, Tenn., June 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement

The Company previously communicated that CMS had calculated a rating of 3.0 Stars for its PPO plans, impacting payment year 2025. As a result of a recent rating recalculation, CMS has improved that rating to 3.5 Stars for 2025 payment year The Company previously communicated that CMS had calculated a rating of 3.0 Stars for its PPO plans, impacting payment year 2025. As a result of a recent rating recalculation, CMS has improved that rating to 3.5 Stars for 2025 payment year

CMS Improves Star Ratings to 3.5 Stars for Clover Health PPO Medicare Advantage Plans for 2025 Payment Year

Alnylam Pharmaceuticals

CRISPR Therapeutics

Enovix Corporation

General American Investors

Halliburton

Logistic Properties Of The Americas

Adams Natural Resources Fund Inc

POET Technologies Inc

Roivant Sciences Ltd

Uranium Royalty Corp

Voyager Therapeutics

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.

The 'Undercovered' Dozen From June 1-6

Clover Health is making its AI-powered technology platform, Clover Assistant, available for other Medicare Advantage payors and providers under the brand name Counterpart Assistant. The new offering will employ a hybrid SaaS and shared-savings revenue model, with options for full capitation, which will boost its margins. Counterpart Assistant could be highly coveted due to its ability to diagnose chronic diseases early, which helps reduce healthcare costs for insurers.

Clover Health: New Business Model Is A Game Changer

FRANKLIN, Tenn., May 29, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, is excited to announce that its flagship clinical decision support tool, Clover Assistant, is now generally available for external payors and providers under the brand name Counterpart Assistant (“CA”). This strategic move with Counterpart Health, a subsidiary of Clover Health, aims to extend the benefits of data-driven proven technology, personalized care to a wider audience, enabling enhanced patient outcomes and reduced healthcare costs across the nation.

Clover Health Announces Counterpart Health, a New SaaS and Tech Enabled Services Solution to Bring the Power of CA Technology to all Medicare Advantage Payors and Providers

Clover Health (NASDAQ: CLOV) stock price went parabolic on Wednesday as investors cheered the company's financial results, forward guidance, and share repurchase program. It surged by over 18%, its best daily performance since August last year.

Here's why Clover Health stock price spiked after earnings

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Ryan Schmidt - IR Andrew Toy - CEO Terrence Ronan - Interim CFO Conference Call Participants Richard Close - Canaccord Genuity Inc. Jason Cassorla - Citigroup Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Clover Health Investments, Corp. (CLOV) Q1 2024 Earnings Call Transcript

Clover Health Investments, Corp. (CLOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.15 per share a year ago.

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

CVS Health

Walgreens

For many investors, the concept of putting money into healthcare stocks to sell them at a future date might seem like a safe investment. After all, almost every person in the United States is dependent upon the corporatized healthcare system in some way or another.

3 Healthcare Stocks to Sell in May Before They Crash & Burn

FRANKLIN, Tenn., April 30, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, announced today that effective April 29, 2024, the Talent and Compensation Committee of the Company's Board of Directors granted a restricted stock unit award (the “RSUs”) to Peter Kuipers, who will be the Company's new Chief Financial Officer effective as of the day after filing of our Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. The RSUs were granted under the Company's 2022 Inducement Award Plan (the “Inducement Plan”) and will be subject to the terms and conditions of an award agreement and the Inducement Plan.

Clover Health Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

FRANKLIN, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 7, 2024, to discuss the Company's business and financial results.

Clover Health to Report First Quarter 2024 Financial Results on May 7, 2024

FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer (“CFO”), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024.

Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

FRANKLIN, Tenn., April 04, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, most recently in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023, Clover Health Investments, Corp. (the "Company") has reached an agreement to resolve shareholder derivative actions pending in four jurisdictions. The actions are captioned: (1) Sun v. Garipalli, et al., No. 3:21-cv-0311 (M.D. Tenn.); (2) In re: Clover Health Investments Corp. Derivative Litig., No. 1:21-cv-00191 (D. Del.); (3) In re Clover Health Investments, Corp. Stockholder Derivative Litig., Index No. 655420/2021 (N.Y. Sup. Ct., N.Y. Cnty.); and (4) Davies v. Garipalli, et al., No. 2021-1016-SG (Del. Ch.) (collectively the "Shareholder Derivative Actions"). The Shareholder Derivative Actions were filed in the wake of the Company's de-SPAC transaction.

Clover Health Provides Notice Associated with Previously Disclosed Settlement of Shareholder Derivative Actions

Opera Ltd - ADR

SNDL Inc.

Numbers frequently take center stage in the stock market's maze. However, every figure has a story of strategy, ingenuity, and resiliency behind it.

3 Under-the-Radar Stocks to Transform $10K into $100K by 2028

Partnership aims to improve outcomes through increased support to underserved and at-risk patient populations through Clover's home-based care model Partnership aims to improve outcomes through increased support to underserved and at-risk patient populations through Clover's home-based care model

Clover Health Launches New Clinical Program in Partnership with Quartet Health to Address Serious Mental Illness

Clover Health Investments, Corp. (CLOV) Q4 2023 Earnings Call Transcript

News for Clover Health Investments Stock (CLOV)